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DRUG ADMINISTRATION
A. Lenalidomide 1. Take lenalidomide by mouth daily around the same time of day without regard to food. 2. Swallow lenalidomide capsules with liquid. B. Bortezomib: Administer intravenously as a rapid IV push over 3 to 5 seconds or as a subcutaneous injection. C. Dexamethasone 1. Dexamethasone is usually given orally as a single daily dose. 2. To avoid gastric irritation, dexamethasone should be taken with food or after a meal.
SUPPORTIVE CARE
A. Acute Emesis Prophylaxis: The RVD regimen is predicted to cause acute emesis in less than 30% of patients. 11, 12 Some of the studies reviewed did not report nausea or emesis 1, 7, 8 ; other studies reviewed reported nausea of any grade in 23% to 32% of patients 2, 3, 6 and grade 3 or 4 nausea in 2% of patients. 4, 5 Because dexamethasone is one of the components of the RVD regimen, additional corticosteroids as part of the antiemetic regimen generally are not necessary. One of the following regimens is suggested on the days when lenalidomide is given 11 less than 10%, routine prophylactic use of CSFs is not recommended. 13 Febrile neutropenia was reported in 2% to 16% of patients, 1,4 while (grade 3 or 4) neutropenia was reported in 7% to 35% of patients. [1] [2] [3] [4] [5] [6] 8 Prophylactic use of CSFs is not recommended. CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of RVD. D. Venous Thromboembolism: Lenalidomide com- bined with dexamethasone in the treatment of multiple myeloma has been associated with an 8% to 75% incidence of venous thromboembolism (VTE). 14 VTE (grade 3 or 4) was reported in 4% to 8% of patients in the RVD studies reviewed, 5, 6, 8 and in all studies patients received anticoagulation prophylaxis with aspirin, warfarin, or low molecular weight heparin. [1] [2] [3] [4] [5] [6] [7] [8] One study suggests that daily low dose aspirin is as effective as low molecular weight heparin or warfarin in the prevention of thromboembolic events secondary to regimens containing dexamethasone and thalidomide, a drug similar to lenalidomide. 15 Current guidelines suggest low dose aspirin in myeloma patients receiving lenalidomide-, thalidomide-, or pomalidomide-based regimens who are at low risk for thromboembolic events and low molecular weight heparin or warfarin international normalized ratio (INR) 2 to 3 for such patients at high risk of thromboembolic events. 16
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf).
Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than 1%.
A. Cardiovascular: Atrial fibrillation (all grades)
5%, 2 a. Grade 1 without pain or loss of function, no dosage reduction required. b. Grade 1 with pain or grade 2, lower dose to 1 mg/m 2 . c. Grade 2 with pain or grade 3, hold and restart at 0.7 mg/m 2 once weekly. d. Grade 4, stop bortezomib. e. Bortezomib administered subcutaneously versus intravenously is associated with decreased incidence of neuropathy, and its use is especially advantageous in patients with risk factors or history of neuropathy. 10, 24 Multiple myeloma guidelines were recently updated with the recommendation for preference of subcutaneous bortezomib in these patient populations. 9 3. Dexamethasone: No dosage reduction necessary. E. Other: For nonhematologic grade 3 or 4 toxicities, hold all drugs and restart lenalidomide with a 5 mg reduction, bortezomib with a 0.3 mg/m 2 reduction, and dexamethasone with a 50% reduction when toxicity has resolved to less than or equal to grade 2. 6,10,17
